Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jason Alexander Efstathiou, M.D., Ph.D.

Title
Institution
Department
Address
Phone
Fax

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Black PC, Efstathiou J. Setting the stage for bladder preservation. Urol Oncol. 2020 Sep 29. PMID: 33008753.
    Citations:    Fields:    
  2. Hall WA, Paulson E, Davis BJ, Spratt DE, Morgan TM, Dearnaley D, Tree AC, Efstathiou JA, Harisinghani M, Jani AB, Buyyounouski MK, Pisansky TM, Tran PT, Karnes RJ, Chen RC, Cury FL, Michalski JM, Rosenthal SA, Koontz BF, Wong AC, Nguyen PL, Hope TA, Feng F, Sandler HM, Lawton CAF. NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. Int J Radiat Oncol Biol Phys. 2020 Aug 27. PMID: 32861817.
    Citations:    Fields:    
  3. Cuenca AG, Rosales I, Lee RJ, Wu CL, Colvin R, Feldman AS, Efstathiou JA, Tolkoff-Rubin N, Elias N. Resolution of a High Grade and Metastatic BK Polyomavirus-Associated Urothelial Cell Carcinoma Following Radical Allograft Nephroureterectomy and Immune Checkpoint Treatment: A Case Report. Transplant Proc. 2020 Nov; 52(9):2720-2725. PMID: 32741665.
    Citations:    Fields:    
  4. Miller LE, Efstathiou JA, Bhattacharyya SK, Payne HA, Woodward E, Pinkawa M. Association of the Placement of a Perirectal Hydrogel Spacer With the Clinical Outcomes of Men Receiving Radiotherapy for Prostate Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020 06 01; 3(6):e208221. PMID: 32585020.
    Citations:    Fields:    
  5. Jackson WC, Hartman HE, Dess RT, Birer SR, Soni PD, Hearn JWD, Reichert ZR, Kishan AU, Mahal BA, Zumsteg ZS, Efstathiou JA, Kaffenberger S, Morgan TM, Mehra R, Showalter TN, Krauss DA, Nguyen PL, Schipper MJ, Feng FY, Sandler HM, Hoskin PJ, Roach M, Spratt DE. Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. J Clin Oncol. 2020 Sep 10; 38(26):3024-3031. PMID: 32396488.
    Citations:    Fields:    
  6. Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, Mahal BA, Stish BJ, Zumsteg ZS, Den RB, Hall WA, Gharzai LA, Jaworski EM, Reichert ZR, Morgan TM, Mehra R, Schaeffer EM, Sartor O, Nguyen PL, Lee WR, Rosenthal SA, Michalski JM, Schipper MJ, Dignam JJ, Pisansky TM, Zietman AL, Sandler HM, Efstathiou JA, Feng FY, Shipley WU, Spratt DE. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol. 2020 May 01; 6(5):735-743. PMID: 32215583.
    Citations:    Fields:    
  7. de Jong JJ, Boormans JL, van Rhijn BWG, Seiler R, Boorjian SA, Konety B, Bivalacqua TJ, Wheeler T, Svatek RS, Douglas J, Wright J, Dall'Era M, Crabb SJ, Efstathiou JA, van der Heijden MS, Mouw KW, Miyamoto DT, Lotan Y, Black PC, Gibb EA, Porten SP. Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. Eur Urol Oncol. 2020 08; 3(4):420-423. PMID: 32205136.
    Citations: 1     Fields:    
  8. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Chang S, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Guzzo T, Herr HW, Hoffman-Censits J, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Michalski J, Montgomery JS, Nandagopal L, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wright JL, Gurski LA, Johnson-Chilla A. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 03; 18(3):329-354. PMID: 32135513.
    Citations: 4     Fields:    
  9. Solanki AA, Efstathiou JA. EDITORIAL COMMENT. Urology. 2019 11; 133:171-172. PMID: 31706416.
    Citations:    Fields:    Translation:Humans
  10. Leow JJ, Catto JWF, Efstathiou JA, Gore JL, Hussein AA, Shariat SF, Smith AB, Weizer AZ, Wirth M, Witjes JA, Trinh QD. Quality Indicators for Bladder Cancer Services: A Collaborative Review. Eur Urol. 2020 Jul; 78(1):43-59. PMID: 31563501.
    Citations:    Fields:    
  11. Salari K, Kuppermann D, Preston MA, Dahl DM, Barrisford GW, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS. Reply by Authors. J Urol. 2019 10; 202(4):821-822. PMID: 31163004.
    Citations:    Fields:    Translation:Humans
  12. Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent Global Patterns in Prostate Cancer Incidence and Mortality Rates. Eur Urol. 2020 01; 77(1):38-52. PMID: 31493960.
    Citations: 15     Fields:    
  13. Muralidhar V, Nguyen PL, Mahal BA, Yang DD, Mouw KW, Rose BS, Beard CJ, Efstathiou JA, Martin NE, King MT, Orio PF. Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. J Natl Compr Canc Netw. 2019 08 01; 17(8):941-948. PMID: 31390585.
    Citations:    Fields:    Translation:Humans
  14. Nogueira LM, Sahar L, Efstathiou JA, Jemal A, Yabroff KR. Association Between Declared Hurricane Disasters and Survival of Patients With Lung Cancer Undergoing Radiation Treatment. JAMA. 2019 07 16; 322(3):269-271. PMID: 31310288.
    Citations: 3     Fields:    Translation:Humans
  15. Fish M, Parkes J, Dharsee N, Dryden-Peterson S, Efstathiou J, Schnipper L, Chabner BA, Parikh AR. POETIC (Program for Enhanced Training in Cancer): An Initial Experience of Supporting Capacity Building for Oncology Training in Sub-Saharan Africa. Oncologist. 2019 12; 24(12):1557-1561. PMID: 31182656.
    Citations: 2     Fields:    Translation:Humans
  16. Iyer HS, Kohler RE, Ramogola-Masire D, Brown C, Molebatsi K, Grover S, Kablay I, Bvochora-Nsingo M, Efstathiou JA, Lockman S, Tapela N, Dryden-Peterson SL. Explaining disparities in oncology health systems delays and stage at diagnosis between men and women in Botswana: A cohort study. PLoS One. 2019; 14(6):e0218094. PMID: 31170274.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  17. Dess RT, Soni PD, Jackson WC, Berlin A, Cox BW, Jolly S, Efstathiou JA, Feng FY, Kishan AU, Stish BJ, Pisansky TM, Spratt DE. The current state of randomized clinical trial evidence for prostate brachytherapy. Urol Oncol. 2019 09; 37(9):599-610. PMID: 31060795.
    Citations: 1     Fields:    Translation:Humans
  18. Kamran SC, Light JO, Efstathiou JA. Proton versus photon-based radiation therapy for prostate cancer: emerging evidence and considerations in the era of value-based cancer care. Prostate Cancer Prostatic Dis. 2019 12; 22(4):509-521. PMID: 30967625.
    Citations:    Fields:    Translation:Humans
  19. Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC. Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clin Cancer Res. 2019 07 01; 25(13):3908-3920. PMID: 30952638.
    Citations: 4     Fields:    Translation:HumansCells
  20. Salari K, Kuppermann D, Preston MA, Dahl DM, Barrisford GW, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS. Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. J Urol. 2019 04; 201(4):721-727. PMID: 30664083.
    Citations: 2     Fields:    Translation:Humans
  21. Mouw KW, Miyamoto DT, Efstathiou JA. Reply from Authors re: Ananya Choudhury, Peter J. Hoskin. Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. Eur Urol 2019;76:69-70: Towards Biomarker-Informed Management of Muscle-Invasive Bladder Cancer. Eur Urol. 2019 07; 76(1):71-72. PMID: 30910345.
    Citations: 1     Fields:    Translation:Humans
  22. Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. J Urol. 2019 03; 201(3):528-534. PMID: 30759696.
    Citations: 5     Fields:    Translation:Humans
  23. Royce TJ, Efstathiou JA. Editorial comment. Urology. 2019 Feb; 124:189-190. PMID: 30784711.
    Citations:    Fields:    Translation:Humans
  24. Efstathiou JA, Choudhury A, Kiltie AE. Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer. JAMA Surg. 2019 02 01; 154(2):184-185. PMID: 30477011.
    Citations:    Fields:    Translation:Humans
  25. Efstathiou JA, Mouw KW, Gibb EA, Liu Y, Wu CL, Drumm MR, da Costa JB, du Plessis M, Wang NQ, Davicioni E, Feng FY, Seiler R, Black PC, Shipley WU, Miyamoto DT. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. Eur Urol. 2019 07; 76(1):59-68. PMID: 30712971.
    Citations: 17     Fields:    Translation:HumansCells
  26. Leow JJ, Bedke J, Chamie K, Collins JW, Daneshmand S, Grivas P, Heidenreich A, Messing EM, Royce TJ, Sankin AI, Schoenberg MP, Shipley WU, Villers A, Efstathiou JA, Bellmunt J, Stenzl A. SIU-ICUD consultation on bladder cancer: treatment of muscle-invasive bladder cancer. World J Urol. 2019 Jan; 37(1):61-83. PMID: 30684034.
    Citations: 2     Fields:    Translation:Humans
  27. Meng W, Efstathiou J, Singh R, McElroy J, Volinia S, Cui R, Ibrahim A, Johnson B, Gupta N, Mehta S, Wang H, Miller E, Nguyen P, Fleming J, Wu CL, Haque SJ, Shipley W, Chakravarti A. MicroRNA Biomarkers for Patients With Muscle-Invasive Bladder Cancer Undergoing Selective Bladder-Sparing Trimodality Treatment. Int J Radiat Oncol Biol Phys. 2019 05 01; 104(1):197-206. PMID: 30583038.
    Citations: 4     Fields:    Translation:HumansCells
  28. Yerramilli D, Moghanaki DM, Efstathiou JA. Safeguarding Autonomy of Patients With Bladder Cancer. Int J Radiat Oncol Biol Phys. 2019 01 01; 103(1):81-83. PMID: 30563669.
    Citations:    Fields:    Translation:Humans
  29. Royce TJ, Efstathiou JA. Proton therapy for prostate cancer: A review of the rationale, evidence, and current state. Urol Oncol. 2019 09; 37(9):628-636. PMID: 30527342.
    Citations:    Fields:    Translation:Humans
  30. Miyamoto DT, Mouw KW, Feng FY, Shipley WU, Efstathiou JA. Molecular biomarkers in bladder preservation therapy for muscle-invasive bladder cancer. Lancet Oncol. 2018 12; 19(12):e683-e695. PMID: 30507435.
    Citations: 9     Fields:    Translation:HumansAnimals
  31. Efstathiou JA, Drumm MR, Paly JP, Lawton DM, O'Neill RM, Niemierko A, Leffert LR, Loeffler JS, Shih HA. Long-term impact of a faculty mentoring program in academic medicine. PLoS One. 2018; 13(11):e0207634. PMID: 30496199.
    Citations: 2     Fields:    Translation:Humans
  32. Solanki AA, Bossi A, Efstathiou JA, Lock D, Mondini M, Ramapriyan R, Welsh J, Kang J. Combining Immunotherapy with Radiotherapy for the Treatment of Genitourinary Malignancies. Eur Urol Oncol. 2019 02; 2(1):79-87. PMID: 30929848.
    Citations: 3     Fields:    Translation:Humans
  33. Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou JA, Jani AB, Kucuk O, Souhami L, Rodgers JP, Sandler HM, Shipley WU. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. J Clin Oncol. 2019 01 01; 37(1):44-51. PMID: 30433852.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  34. Hwang WL, Niemierko A, Efstathiou JA. Comparing Adjuvant vs Early-Salvage Radiotherapy After Radical Prostatectomy-Reply. JAMA Oncol. 2018 11 01; 4(11):1620-1621. PMID: 30422248.
    Citations:    Fields:    Translation:Humans
  35. Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Pract Radiat Oncol. 2018 Nov - Dec; 8(6):354-360. PMID: 30322661.
    Citations: 17     Fields:    Translation:Humans
  36. Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. J Clin Oncol. 2018 Oct 11; JCO1801097. PMID: 30307776.
    Citations: 18     Fields:    
  37. Morgan SC, Hoffman K, Loblaw DA, Buyyounouski MK, Patton C, Barocas D, Bentzen S, Chang M, Efstathiou J, Greany P, Halvorsen P, Koontz BF, Lawton C, Leyrer CM, Lin D, Ray M, Sandler H. Hypofractionated Radiation Therapy for Localized Prostate Cancer: An ASTRO, ASCO, and AUA Evidence-Based Guideline. J Urol. 2018 Oct 09. PMID: 30316897.
    Citations:    Fields:    
  38. Royce TJ, Feldman AS, Mossanen M, Yang JC, Shipley WU, Pandharipande PV, Efstathiou JA. Comparative Effectiveness of Bladder-preserving Tri-modality Therapy Versus Radical Cystectomy for Muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2019 Feb; 17(1):23-31.e3. PMID: 30482661.
    Citations: 4     Fields:    Translation:Humans
  39. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Downs TM, Efstathiou JA, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak DP, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Tward J, Wile G, Johnson-Chilla A, Dwyer MA, Gurski LA. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. J Natl Compr Canc Netw. 2018 09; 16(9):1041-1053. PMID: 30181416.
    Citations: 19     Fields:    Translation:Humans
  40. Sargos P, Baumann BC, Eapen L, Christodouleas J, Bahl A, Murthy V, Efstathiou J, Fonteyne V, Ballas L, Zaghloul M, Roubaud G, Orré M, Larré S. Risk factors for loco-regional recurrence after radical cystectomy of muscle-invasive bladder cancer: A systematic-review and framework for adjuvant radiotherapy. Cancer Treat Rev. 2018 Nov; 70:88-97. PMID: 30125800.
    Citations: 4     Fields:    Translation:Humans
  41. Moteabbed M, Trofimov A, Khan FH, Wang Y, Sharp GC, Zietman AL, Efstathiou JA, Lu HM. Impact of interfractional motion on hypofractionated pencil beam scanning proton therapy and VMAT delivery for prostate cancer. Med Phys. 2018 Jul 14. PMID: 30007067.
    Citations:    Fields:    
  42. Lukka HR, Pugh SL, Bruner DW, Bahary JP, Lawton CAF, Efstathiou JA, Kudchadker RJ, Ponsky LE, Seaward SA, Dayes IS, Gopaul DD, Michalski JM, Delouya G, Kaplan ID, Horwitz EM, Roach M, Pinover WH, Beyer DC, Amanie JO, Sandler HM, Kachnic LA. Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 10 01; 102(2):287-295. PMID: 29913254.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  43. Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, Hearn JW, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz MC, Pollack A, Moghanaki D, Anscher MS, Den RB, Zietman AL, Stephenson AJ, Efstathiou JA. Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncol. 2018 05 10; 4(5):e175230. PMID: 29372236.
    Citations: 8     Fields:    Translation:Humans
  44. Panebianco V, Narumi Y, Altun E, Bochner BH, Efstathiou JA, Hafeez S, Huddart R, Kennish S, Lerner S, Montironi R, Muglia VF, Salomon G, Thomas S, Vargas HA, Witjes JA, Takeuchi M, Barentsz J, Catto JWF. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). Eur Urol. 2018 09; 74(3):294-306. PMID: 29755006.
    Citations: 15     Fields:    Translation:Humans
  45. Bryant AK, Kader AK, McKay RR, Einck JP, Mell LK, Mundt AJ, Kane CJ, Efstathiou JA, Murphy JD, Rose BS. Definitive Radiation Therapy and Survival in Clinically Node-Positive Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 08 01; 101(5):1188-1193. PMID: 29891203.
    Citations: 1     Fields:    Translation:Humans
  46. Liu Q, Gheorghiu L, Drumm M, Clayman R, Eidelman A, Wszolek MF, Olumi A, Feldman A, Wang M, Marcar L, Citrin DE, Wu CL, Benes CH, Efstathiou JA, Willers H. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53. Oncogene. 2018 05; 37(21):2793-2805. PMID: 29511347.
    Citations: 4     Fields:    Translation:HumansCells
  47. Miyamoto DT, Lee RJ, Kalinich M, LiCausi JA, Zheng Y, Chen T, Milner JD, Emmons E, Ho U, Broderick K, Silva E, Javaid S, Kwan TT, Hong X, Dahl DM, McGovern FJ, Efstathiou JA, Smith MR, Sequist LV, Kapur R, Wu CL, Stott SL, Ting DT, Giobbie-Hurder A, Toner M, Maheswaran S, Haber DA. An RNA-Based Digital Circulating Tumor Cell Signature Is Predictive of Drug Response and Early Dissemination in Prostate Cancer. Cancer Discov. 2018 03; 8(3):288-303. PMID: 29301747.
    Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
  48. Harshman LC, Tripathi A, Kaag M, Efstathiou JA, Apolo AB, Hoffman-Censits JH, Stadler WM, Yu EY, Bochner BH, Skinner EC, Downs T, Kiltie AE, Bajorin DF, Guru K, Shipley WU, Steinberg GD, Hahn NM, Sridhar SS. Contemporary Patterns of Multidisciplinary Care in Patients With Muscle-invasive Bladder Cancer. Clin Genitourin Cancer. 2018 06; 16(3):213-218. PMID: 29289519.
    Citations:    Fields:    Translation:Humans
  49. Wo JY, Drapek LC, Niemierko A, Silvia B, Noé BN, Russo AL, Miyamoto DT, Hong TS, Efstathiou JA, Zietman AL, Dizon DS. Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. Pract Radiat Oncol. 2018 May - Jun; 8(3):206-212. PMID: 29426693.
    Citations:    Fields:    Translation:Humans
  50. Royce TJ, Lin CC, Gray PJ, Shipley WU, Jemal A, Efstathiou JA. Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: Results from the National Cancer Data Base. Urol Oncol. 2018 02; 36(2):78.e1-78.e12. PMID: 29162314.
    Citations: 3     Fields:    Translation:Humans
  51. Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, Michalski JM, Spratt DE, Hearn JWD, Koontz BF, Liauw SL, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. Eur Urol. 2018 07; 74(1):99-106. PMID: 29128208.
    Citations: 4     Fields:    Translation:Humans
  52. Müller BS, Shih HA, Efstathiou JA, Bortfeld T, Craft D. Multicriteria plan optimization in the hands of physicians: a pilot study in prostate cancer and brain tumors. Radiat Oncol. 2017 Nov 06; 12(1):168. PMID: 29110689.
    Citations: 3     Fields:    Translation:Humans
  53. Gakis G, Schubert T, Morgan TM, Daneshmand S, Keegan KA, Mischinger J, Clayman RH, Brisuda A, Ali-El-Dein B, Galland S, Gregg J, Balci M, Olugbade K, Rink M, Fritsche HM, Burger M, Babjuk M, Stenzl A, Thalmann GN, Kübler H, Efstathiou JA. The prognostic effect of salvage surgery and radiotherapy in patients with recurrent primary urethral carcinoma. Urol Oncol. 2018 01; 36(1):10.e7-10.e14. PMID: 29055518.
    Citations: 2     Fields:    Translation:Humans
  54. Ahamad A, Martinez A, Salenius S, Ross R, Efstathiou J, Fernandez E. Routine bladder cancer treatment dictates divergence from trial-derived regimens: Results of treatment at 44 radiotherapy centers. Urol Oncol. 2018 01; 36(1):9.e19-9.e25. PMID: 28993060.
    Citations:    Fields:    Translation:Humans
  55. Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Clark PE, Downs TM, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Jimbo M, Kader AK, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Preston MA, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Gurski LA. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 10; 15(10):1240-1267. PMID: 28982750.
    Citations: 51     Fields:    Translation:Humans
  56. Sanchez A, Wszolek MF, Niemierko A, Clayman RH, Drumm M, Rodríguez D, Feldman AS, Dahl DM, Heney NM, Shipley WU, Zietman AL, Efstathiou JA. Incidence, Clinicopathological Risk Factors, Management and Outcomes of Nonmuscle Invasive Recurrence after Complete Response to Trimodality Therapy for Muscle Invasive Bladder Cancer. J Urol. 2018 02; 199(2):407-415. PMID: 28870862.
    Citations: 5     Fields:    Translation:Humans
  57. Rodin D, Drumm M, Clayman R, Buscariollo DL, Galland-Girodet S, Eidelman A, Feldman AS, Dahl DM, McGovern FJ, Olumi AF, Niemierko A, Shipley WU, Zietman AL, Efstathiou JA. Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience. Clin Genitourin Cancer. 2017 Aug 03. PMID: 28864223.
    Citations: 2     Fields:    
  58. Giacalone NJ, Niemierko A, Shipley WU, Efstathiou JA. Reply to Saeid Safiri and Erfan Ayubi's Letter to the Editor re: Nicholas J. Giacalone, William U. Shipley, Rebecca H. Clayman, et al. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017;71:952-60. Methodological Issues to Avoid Misinterpretation. Eur Urol. 2017 09; 72(3):e64-e65. PMID: 28642020.
    Citations:    Fields:    Translation:Humans
  59. Jang JW, Drumm MR, Efstathiou JA, Paly JJ, Niemierko A, Ancukiewicz M, Talcott JA, Clark JA, Zietman AL. Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade. Cancer Med. 2017 Jul; 6(7):1827-1836. PMID: 28560840.
    Citations: 8     Fields:    Translation:Humans
  60. Xiang HF, Lu HM, Efstathiou JA, Zietman AL, De Armas R, Harris K, Bloch BN, Qureshi MM, Keohan S, Hirsch AE. Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy (SBRT) for early-stage prostate cancer. J Appl Clin Med Phys. 2017 05; 18(3):37-43. PMID: 28407345.
    Citations: 1     Fields:    Translation:HumansPHPublic Health
  61. Chin J, Rumble RB, Kollmeier M, Heath E, Efstathiou J, Dorff T, Berman B, Feifer A, Jacques A, Loblaw DA. Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update. J Clin Oncol. 2017 May 20; 35(15):1737-1743. PMID: 28346805.
    Citations: 13     Fields:    Translation:Humans
  62. Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, Lu HM. Proton therapy of prostate cancer by anterior-oblique beams: implications of setup and anatomy variations. Phys Med Biol. 2017 03 07; 62(5):1644-1660. PMID: 28166057.
    Citations: 2     Fields:    Translation:Humans
  63. Baumann BC, Sargos P, Eapen LJ, Efstathiou JA, Choudhury A, Bahl A, Murthy V, Ballas LK, Fonteyne V, Richaud PM, Zaghloul MS, Christodouleas JP. The Rationale for Post-Operative Radiation in Localized Bladder Cancer. Bladder Cancer. 2017 Jan 27; 3(1):19-30. PMID: 28149931.
    Citations: 5     
  64. Kamran SC, Harshman LC, Bhagwat MS, Muralidhar V, Nguyen PL, Martin NE, La Follette S, Faso S, Viswanathan AN, Efstathiou JA, Beard CJ. Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience. Adv Radiat Oncol. 2017 Apr-Jun; 2(2):140-147. PMID: 28740925.
    Citations: 2     
  65. Underwood TS, Voog JC, Moteabbed M, Tang S, Soffen E, Cahlon O, Lu HM, Zietman AL, Efstathiou JA, Paganetti H. Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams. Acta Oncol. 2017 Apr; 56(4):575-581. PMID: 28075206.
    Citations:    Fields:    Translation:Humans
  66. Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol. 2017 06; 71(6):952-960. PMID: 28081860.
    Citations: 25     Fields:    Translation:Humans
  67. van Soest RJ, Efstathiou JA, Sternberg CN, Tombal B. The Natural History and Outcome Predictors of Metastatic Castration-resistant Prostate Cancer. Eur Urol Focus. 2016 Dec; 2(5):480-487. PMID: 28723513.
    Citations: 2     Fields:    
  68. Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu CL, Wu S, Zhang J, Heney NM, Wszolek MF, Blute ML, Feldman AS, Lee RJ, Zietman AL, Shipley WU, Efstathiou JA. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. Eur Urol. 2017 07; 72(1):54-60. PMID: 28040351.
    Citations: 7     Fields:    Translation:Humans
  69. Smith GL, Ganz PA, Bekelman JE, Chmura SJ, Dignam JJ, Efstathiou JA, Jagsi R, Johnstone PA, Steinberg ML, Williams SB, Yu JB, Zietman AL, Weichselbaum RR, Tina Shih YC. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. Int J Radiat Oncol Biol Phys. 2017 03 01; 97(3):450-461. PMID: 28011046.
    Citations: 5     Fields:    Translation:Humans
  70. Dryden-Peterson S, Bvochora-Nsingo M, Suneja G, Efstathiou JA, Grover S, Chiyapo S, Ramogola-Masire D, Kebabonye-Pusoentsi M, Clayman R, Mapes AC, Tapela N, Asmelash A, Medhin H, Viswanathan AN, Russell AH, Lin LL, Kayembe MKA, Mmalane M, Randall TC, Chabner B, Lockman S. HIV Infection and Survival Among Women With Cervical Cancer. J Clin Oncol. 2016 11 01; 34(31):3749-3757. PMID: 27573661.
    Citations: 18     Fields:    Translation:Humans
  71. Muralidhar V, Mahal BA, Rose BS, Chen YW, Nezolosky MD, Efstathiou JA, Beard CJ, Martin NE, Orio PF, Trinh QD, Choueiri TK, Sweeney CJ, Nguyen PL. Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clin Genitourin Cancer. 2017 10; 15(5):563-569.e3. PMID: 28462857.
    Citations:    Fields:    Translation:Humans
  72. Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol. 2016 Oct 20; 34(30):3648-3654. PMID: 27528718.
    Citations: 45     Fields:    
  73. Buscariollo DL, Drumm M, Niemierko A, Clayman RH, Galland-Girodet S, Rodin D, Feldman AS, M Dahl D, McGovern FJ, F Olumi A, Eidelman A, Shipley WU, Zietman AL, Efstathiou JA. Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. Pract Radiat Oncol. 2017 Mar - Apr; 7(2):e125-e133. PMID: 28274403.
    Citations: 4     Fields:    Translation:Humans
  74. Efstathiou JA. Introduction. Semin Radiat Oncol. 2017 01; 27(1):1-2. PMID: 27986206.
    Citations:    Fields:    Translation:HumansPHPublic Health
  75. Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 10; 14(10):1213-1224. PMID: 27697976.
    Citations: 29     Fields:    Translation:Humans
  76. Sargos P, Baumann BC, Eapen LJ, Bahl A, Murthy V, Roubaud G, Orré M, Efstathiou JA, Shariat S, Larré S, Richaud P, Christodouleas JP. Adjuvant radiotherapy for pathological high-risk muscle invasive bladder cancer: time to reconsider? Transl Androl Urol. 2016 Oct; 5(5):702-710. PMID: 27785427.
    Citations: 5     
  77. Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA, Michalski JM, Feng FY, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ, Tendulkar RD. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):1046-1053. PMID: 27745980.
    Citations: 8     Fields:    Translation:Humans
  78. Gray PJ, Lin CC, Cooperberg MR, Jemal A, Efstathiou JA. Temporal Trends and the Impact of Race, Insurance, and Socioeconomic Status in the Management of Localized Prostate Cancer. Eur Urol. 2017 05; 71(5):729-737. PMID: 27597241.
    Citations: 15     Fields:    Translation:Humans
  79. Mak KS, Smith AB, Eidelman A, Clayman R, Niemierko A, Cheng JS, Matthews J, Drumm MR, Nielsen ME, Feldman AS, Lee RJ, Zietman AL, Chen RC, Shipley WU, Milowsky MI, Efstathiou JA. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2016 12 01; 96(5):1028-1036. PMID: 27727064.
    Citations: 16     Fields:    Translation:Humans
  80. Roberts HJ, Zietman AL, Efstathiou JA. Painting Dose: The ART of Radiation. Int J Radiat Oncol Biol Phys. 2016 11 15; 96(4):722-728. PMID: 27788945.
    Citations:    Fields:    Translation:Humans
  81. Gakis G, Efstathiou JA, Daneshmand S, Keegan KA, Clayman RH, Hrbacek J, Ali-El-Dein B, Zaid HB, Schubert T, Mischinger J, Todenhöfer T, Galland S, Olugbade K, Rink M, Fritsche HM, Burger M, Chang SS, Babjuk M, Thalmann GN, Stenzl A, Morgan TM. Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma. Urol Int. 2016; 97(2):134-41. PMID: 27462702.
    Citations: 1     Fields:    Translation:Humans
  82. Moon DH, Efstathiou JA, Chen RC. What is the best way to radiate the prostate in 2016? Urol Oncol. 2017 02; 35(2):59-68. PMID: 27395453.
    Citations: 9     Fields:    Translation:Humans
  83. Mak RH, Hunt D, Efstathiou JA, Heney NM, Jones CU, Lukka HR, Bahary JP, Patel M, Balogh A, Nabid A, Leibenhaut MH, Hamstra DA, Roof KS, Jeffrey Lee R, Gore EM, Sandler HM, Shipley WU. Acute and late urinary toxicity following radiation in men with an intact prostate gland or after a radical prostatectomy: A secondary analysis of RTOG 94-08 and 96-01. Urol Oncol. 2016 10; 34(10):430.e1-7. PMID: 27381895.
    Citations: 1     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
  84. Benedict SH, Hoffman K, Martel MK, Abernethy AP, Asher AL, Capala J, Chen RC, Chera B, Couch J, Deye J, Efstathiou JA, Ford E, Fraass BA, Gabriel PE, Huser V, Kavanagh BD, Khuntia D, Marks LB, Mayo C, McNutt T, Miller RS, Moore KL, Prior F, Roelofs E, Rosenstein BS, Sloan J, Theriault A, Vikram B. Overview of the American Society for Radiation Oncology-National Institutes of Health-American Association of Physicists in Medicine Workshop 2015: Exploring Opportunities for Radiation Oncology in the Era of Big Data. Int J Radiat Oncol Biol Phys. 2016 07 01; 95(3):873-879. PMID: 27302503.
    Citations: 10     Fields:    Translation:Humans
  85. Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W. Bladder cancer. Lancet. 2016 12 03; 388(10061):2796-2810. PMID: 27345655.
    Citations: 174     Fields:    Translation:Humans
  86. Makufa R, Bvochora-Nsingo M, Karumekayi T, Schneider RJ, Efstathiou JA, Dryden-Peterson S, Odom A, Shulman A, Pipman Y, Gierga DP. SU-F-P-09: A Global Medical Physics Collaboration for Implementation of Modern Radiotherapy in Botswana. Med Phys. 2016 Jun; 43(6):3359-3360. PMID: 28047638.
    Citations:    
  87. Moteabbed M, Trofimov A, Sharp G, Wang Y, Zietman A, Efstathiou J, Lu H. SU-G-JeP4-09: Impact of Interfractional Motion On Hypofractionated Pencil Beam Scanning Proton Therapy for Prostate Cancer. Med Phys. 2016 Jun; 43(6):3683. PMID: 28046335.
    Citations:    
  88. Paly JJ, Lin CC, Gray PJ, Hallemeier CL, Beard C, Sineshaw H, Jemal A, Efstathiou JA. Management and outcomes of clinical stage IIA/B seminoma: Results from the National Cancer Data Base 1998-2012. Pract Radiat Oncol. 2016 Nov - Dec; 6(6):e249-e258. PMID: 27345128.
    Citations: 3     Fields:    Translation:Humans
  89. Baumann BC, Bosch WR, Bahl A, Birtle AJ, Breau RH, Challapalli A, Chang AJ, Choudhury A, Daneshmand S, El-Gayed A, Feldman A, Finkelstein SE, Guzzo TJ, Hilman S, Jani A, Malkowicz SB, Mantz CA, Master V, Mitra AV, Murthy V, Porten SP, Richaud PM, Sargos P, Efstathiou JA, Eapen LJ, Christodouleas JP. Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):78-86. PMID: 27511849.
    Citations: 12     Fields:    Translation:Humans
  90. Hedgire S, Tonyushkin A, Kilcoyne A, Efstathiou JA, Hahn PF, Harisinghani M. Quantitative study of prostate cancer using three dimensional fiber tractography. World J Radiol. 2016 Apr 28; 8(4):397-402. PMID: 27158426.
    Citations:    
  91. Shah A, Ricci KI, Efstathiou JA. Beyond a moonshot: insurance coverage for proton therapy. Lancet Oncol. 2016 05; 17(5):559-61. PMID: 27301029.
    Citations: 3     Fields:    Translation:Humans
  92. Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2016 Apr 27; 2(2):165-202. PMID: 27376138.
    Citations: 6     
  93. Kamat AM, Agarwal P, Bivalacqua T, Chisolm S, Daneshmand S, Doroshow JH, Efstathiou JA, Galsky M, Iyer G, Kassouf W, Shah J, Taylor J, Williams SB, Quale DZ, Rosenberg JE. Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. Bladder Cancer. 2016 Apr 27; 2(2):203-213. PMID: 27376139.
    Citations: 1     
  94. Brown CA, Suneja G, Tapela N, Mapes A, Pusoentsi M, Mmalane M, Hodgeman R, Boyer M, Musimar Z, Ramogola-Masire D, Grover S, Nsingo-Bvochora M, Kayembe M, Efstathiou J, Lockman S, Dryden-Peterson S. Predictors of Timely Access of Oncology Services and Advanced-Stage Cancer in an HIV-Endemic Setting. Oncologist. 2016 06; 21(6):731-8. PMID: 27053501.
    Citations: 9     Fields:    Translation:Humans
  95. Mahal BA, Chen YW, Efstathiou JA, Muralidhar V, Hoffman KE, Yu JB, Feng FY, Beard CJ, Martin NE, Orio PF, Nguyen PL. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer. 2016 05 15; 122(10):1505-12. PMID: 26970022.
    Citations: 8     Fields:    Translation:Humans
  96. Voog JC, Smith MR, Efstathiou JA. Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA. 2016 Mar 08; 315(10):1054-5. PMID: 26954419.
    Citations:    Fields:    Translation:Humans
  97. Gray PJ, Efstathiou JA, Shipley WU. Words of Wisdom. Re: Radical Cystectomy vs. Chemoradiation in T2-4aN0M0 Bladder Cancer: A Case-control Study. Eur Urol. 2016 Apr; 69(4):757-8. PMID: 26972501.
    Citations:    Fields:    Translation:Humans
  98. Liu Q, Underwood TSA, Kung J, Wang M, Lu HM, Paganetti H, Held KD, Hong TS, Efstathiou JA, Willers H. Disruption of SLX4-MUS81 Function Increases the Relative Biological Effectiveness of Proton Radiation. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):78-85. PMID: 27084631.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  99. Underwood T, Giantsoudi D, Moteabbed M, Zietman A, Efstathiou J, Paganetti H, Lu HM. Can We Advance Proton Therapy for Prostate? Considering Alternative Beam Angles and Relative Biological Effectiveness Variations When Comparing Against Intensity Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):454-464. PMID: 27084660.
    Citations: 6     Fields:    Translation:HumansCells
  100. Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, Lu HM. A Prospective Comparison of the Effects of Interfractional Variations on Proton Therapy and Intensity Modulated Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2016 May 01; 95(1):444-453. PMID: 26907917.
    Citations: 3     Fields:    Translation:Humans
  101. Elmore SN, Sethi RV, Viswanathan AN, Efstathiou JA. Global Radiation Oncology From the Trainee Perspective: A View From Beyond the Bunker. Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):438-9. PMID: 26867872.
    Citations:    Fields:    
  102. Efstathiou JA, Heunis M, Karumekayi T, Makufa R, Bvochora-Nsingo M, Gierga DP, Suneja G, Grover S, Kasese J, Mmalane M, Moffat H, von Paleske A, Makhema J, Dryden-Peterson S. Establishing and Delivering Quality Radiation Therapy in Resource-Constrained Settings: The Story of Botswana. J Clin Oncol. 2016 Jan 01; 34(1):27-35. PMID: 26578607.
    Citations: 6     Fields:    Translation:Humans
  103. Rosenstein BS, Capala J, Efstathiou JA, Hammerbacher J, Kerns SL, Kong FS, Ostrer H, Prior FW, Vikram B, Wong J, Xiao Y. How Will Big Data Improve Clinical and Basic Research in Radiation Therapy? Int J Radiat Oncol Biol Phys. 2016 07 01; 95(3):895-904. PMID: 26797542.
    Citations: 9     Fields:    Translation:Humans
  104. Voog JC, Efstathiou JA. Treatment Trends for Prostate Cancer. JAMA. 2015 Nov 10; 314(18):1976-7. PMID: 26547472.
    Citations:    Fields:    Translation:Humans
  105. Ngwa W, Ngoma T, Zietman A, Mayr N, Elzawawy A, Winningham TA, Balogun O, Enwerem-Bromson N, Ntizimira C, Olopade OI, Oluwole D, Odedina F, Williams M, Flanigan J, Asana L, Ngwa K, Avery S, Pollard JM, Roland T, Funwi-gabga N, Mbarika V, Hardenbergh P, Winkfield K, Pipman Y, Stefan C, Ngoma M, Mohammed S, Katz M, Erno S, Moni J, Fitzgerald T, Tonlaar N, Efstathiou J, Gierga D, Ayo C, Knaul F, Gospodarowicz M, Makrigiorgos GM, Nguyen PL. Closing the Cancer Divide Through Ubuntu: Information and Communication Technology-Powered Models for Global Radiation Oncology. Int J Radiat Oncol Biol Phys. 2016 Mar 01; 94(3):440-9. PMID: 26867873.
    Citations: 5     Fields:    Translation:Humans
  106. Grover S, Raesima M, Bvochora-Nsingo M, Chiyapo SP, Balang D, Tapela N, Balogun O, Kayembe MK, Russell AH, Monare B, Tanyala S, Bhat J, Thipe K, Nchunga M, Mayisela S, Kizito B, Ho-Foster A, Gaolebale BE, Gaolebale PA, Efstathiou JA, Dryden-Peterson S, Zetola N, Hahn SM, Robertson ES, Lin LL, Morroni C, Ramogola-Masire D. Cervical Cancer in Botswana: Current State and Future Steps for Screening and Treatment Programs. Front Oncol. 2015; 5:239. PMID: 26579491.
    Citations: 13     
  107. Voog JC, Paulus R, Efstathiou JA. Reply from Authors re: Ronald C. Chen. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome? Eur Urol 2016;69:211-2: Outcomes for Favorable and Unfavorable Intermediate Risk Prostate Cancer Patients Receiving Radiation Therapy With or Without Short-term Androgen Deprivation Therapy. Eur Urol. 2016 Feb; 69(2):212-3. PMID: 26443430.
    Citations:    Fields:    Translation:Humans
  108. Mahal BA, Aizer AA, Efstathiou JA, Nguyen PL. Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. Cancer. 2016 Jan 01; 122(1):78-83. PMID: 26371600.
    Citations: 7     Fields:    Translation:Humans
  109. Voog JC, Paulus R, Shipley WU, Smith MR, McGowan DG, Jones CU, Bahary JP, Zeitzer KL, Souhami L, Leibenhaut MH, Rotman M, Husain SM, Gore E, Raben A, Chafe S, Sandler HM, Efstathiou JA. Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08. Eur Urol. 2016 Feb; 69(2):204-10. PMID: 26362090.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  110. Muralidhar V, Mahal BA, Nezolosky MD, Beard CJ, Feng FY, Martin NE, Efstathiou JA, Choueiri TK, Pomerantz MM, Sweeney CJ, Trinh QD, Vander Heiden MG, Nguyen PL. Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU Int. 2016 Aug; 118(2):279-85. PMID: 26235660.
    Citations: 3     Fields:    Translation:Humans
  111. Lin CC, Gray PJ, Jemal A, Efstathiou JA. Response. J Natl Cancer Inst. 2015 Sep; 107(9). PMID: 26209711.
    Citations:    Fields:    Translation:Humans
  112. Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, Lu H. SU-E-T-457: Impact of Interfractional Variations On Anterior Vs. Lateral-Field Proton Therapy of Prostate Cancer. Med Phys. 2015 Jun; 42(6):3439. PMID: 26128119.
    Citations:    
  113. Underwood T, Giantsoudi D, Moteabbed M, Zietman A, Efstathiou J, Paganetti H, Lu HM. TU-EF-304-05: Anterior Proton Beams for Prostate Treatments Lead to Substantial Elevations in Modeled RBE-Weighted Rectal Dose. Med Phys. 2015 Jun; 42(6):3615. PMID: 26128957.
    Citations:    
  114. Gakis G, Morgan TM, Efstathiou JA, Keegan KA, Mischinger J, Todenhoefer T, Schubert T, Zaid HB, Hrbacek J, Ali-El-Dein B, Clayman RH, Galland S, Olugbade K, Rink M, Fritsche HM, Burger M, Chang SS, Babjuk M, Thalmann GN, Stenzl A, Daneshmand S. Prognostic factors and outcomes in primary urethral cancer: results from the international collaboration on primary urethral carcinoma. World J Urol. 2016 Jan; 34(1):97-103. PMID: 25981402.
    Citations: 6     Fields:    Translation:Humans
  115. Willers H, Gheorghiu L, Liu Q, Efstathiou JA, Wirth LJ, Krause M, von Neubeck C. DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity. Semin Radiat Oncol. 2015 Oct; 25(4):237-50. PMID: 26384272.
    Citations: 20     Fields:    Translation:Humans
  116. Gakis G, Morgan TM, Daneshmand S, Keegan KA, Todenhöfer T, Mischinger J, Schubert T, Zaid HB, Hrbacek J, Ali-El-Dein B, Clayman RH, Galland S, Olugbade K, Rink M, Fritsche HM, Burger M, Chang SS, Babjuk M, Thalmann GN, Stenzl A, Efstathiou JA. Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma. Ann Oncol. 2015 Aug; 26(8):1754-9. PMID: 25969370.
    Citations: 7     Fields:    Translation:Humans
  117. Lin CC, Gray PJ, Jemal A, Efstathiou JA. Androgen deprivation with or without radiation therapy for clinically node-positive prostate cancer. J Natl Cancer Inst. 2015 Jul; 107(7). PMID: 25957435.
    Citations: 8     Fields:    Translation:Humans
  118. Buchwald ZS, Efstathiou JA. Words of wisdom. Re: MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Eur Urol. 2015 May; 67(5):975. PMID: 25845961.
    Citations: 2     Fields:    Translation:Humans
  119. Buchwald ZS, Efstathiou JA. Immunotherapy and Radiation - A New Combined Treatment Approach for Bladder Cancer? Bladder Cancer. 2015 Apr 30; 1(1):15-27. PMID: 30561443.
    Citations: 7     
  120. Sineshaw HM, Gray PJ, Efstathiou JA, Jemal A. Declining Use of Radiotherapy for Adverse Features After Radical Prostatectomy: Results From the National Cancer Data Base. Eur Urol. 2015 Nov; 68(5):768-74. PMID: 25896124.
    Citations: 18     Fields:    Translation:Humans
  121. Liu Q, Ghosh P, Magpayo N, Testa M, Tang S, Gheorghiu L, Biggs P, Paganetti H, Efstathiou JA, Lu HM, Held KD, Willers H. Lung cancer cell line screen links fanconi anemia/BRCA pathway defects to increased relative biological effectiveness of proton radiation. Int J Radiat Oncol Biol Phys. 2015 Apr 01; 91(5):1081-9. PMID: 25832698.
    Citations: 24     Fields:    Translation:HumansCells
  122. Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O'Donnell MA, Uchio E, Efstathiou JA, Taylor JA. Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol. 2015 04; 12(4):225-35. PMID: 25800393.
    Citations: 24     Fields:    Translation:Humans
  123. Liu Q, Wang M, Kern AM, Khaled S, Han J, Yeap BY, Hong TS, Settleman J, Benes CH, Held KD, Efstathiou JA, Willers H. Adapting a drug screening platform to discover associations of molecular targeted radiosensitizers with genomic biomarkers. Mol Cancer Res. 2015 Apr; 13(4):713-20. PMID: 25667133.
    Citations: 8     Fields:    Translation:HumansCells
  124. Moteabbed M, Sharp GC, Wang Y, Trofimov A, Efstathiou JA, Lu HM. Validation of a deformable image registration technique for cone beam CT-based dose verification. Med Phys. 2015 Jan; 42(1):196-205. PMID: 25563260.
    Citations: 4     Fields:    Translation:Humans
  125. Aizer AA, Gu X, Chen MH, Choueiri TK, Martin NE, Efstathiou JA, Hyatt AS, Graham PL, Trinh QD, Hu JC, Nguyen PL. Cost implications and complications of overtreatment of low-risk prostate cancer in the United States. J Natl Compr Canc Netw. 2015 Jan; 13(1):61-8. PMID: 25583770.
    Citations: 19     Fields:    Translation:Humans
  126. Jani AB, Efstathiou JA, Shipley WU. Bladder preservation strategies. Hematol Oncol Clin North Am. 2015 Apr; 29(2):289-300, ix. PMID: 25836935.
    Citations:    Fields:    Translation:Humans
  127. Mahal BA, Hoffman KE, Efstathiou JA, Nguyen PL. National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009. Clin Genitourin Cancer. 2015 Jun; 13(3):e167-72. PMID: 25554010.
    Citations: 3     Fields:    Translation:Humans
  128. Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014 Dec 01; 32(34):3801-9. PMID: 25366678.
    Citations: 59     Fields:    Translation:Humans
  129. Gray PJ, Lin CC, Sineshaw H, Paly JJ, Jemal A, Efstathiou JA. Management trends in stage I testicular seminoma: Impact of race, insurance status, and treatment facility. Cancer. 2015 Mar 01; 121(5):681-7. PMID: 25345675.
    Citations: 6     Fields:    Translation:Humans
  130. Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, Lotan Y. Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urol Oncol. 2015 Feb; 33(2):53-64. PMID: 25065704.
    Citations: 3     Fields:    Translation:HumansAnimals
  131. Efstathiou JA, Bvochora-Nsingo M, Gierga DP, Alphonse Kayembe MK, Mmalane M, Russell AH, Paly JJ, Brown C, Musimar Z, Abramson JS, Bruce KA, Karumekayi T, Clayman R, Hodgeman R, Kasese J, Makufa R, Bigger E, Suneja G, Busse PM, Randall TC, Chabner BA, Dryden-Peterson S. Addressing the growing cancer burden in the wake of the AIDS epidemic in Botswana: The BOTSOGO collaborative partnership. Int J Radiat Oncol Biol Phys. 2014 Jul 01; 89(3):468-75. PMID: 24929156.
    Citations: 9     Fields:    Translation:HumansPHPublic Health
  132. Bvochara-Nsingo M, Grover S, Gierga DP, Makufa R, Efstathiou JA, Dixit N, Clayman RH, Russell AH, Lin LL, Kasese J. Cervical brachytherapy exchange: steps toward oncology capacity building in Botswana. Oncologist. 2014 Jul; 19(7):e1-2. PMID: 24928614.
    Citations: 6     Fields:    Translation:Humans
  133. Moteabbed M, Trofimov A, Testa M, Sharp G, Wang Y, Paganetti H, Zietman A, Efstathiou J, Lu H. SU-E-T-616: Comparison of Plan Dose Accuracy for Anterior Vs. Lateral Fields in Proton Therapy of Prostate Cancer. Med Phys. 2014 Jun; 41(6):369. PMID: 28037706.
    Citations:    
  134. Xiang H, Qureshi M, De Armas R, Hirsch A, Katz M, Nicholas B, Keohan S, Lu H, Efstathiou J, Zietman A, Willins J, Kachnic J. SU-E-J-150: Impact of Intrafractional Prostate Motion On the Accuracy and Efficiency of Prostate SBRT Delivery: A Retrospective Analysis of Prostate Tracking Log Files. Med Phys. 2014 Jun; 41(6):190-191. PMID: 28036665.
    Citations:    
  135. Ramogola-Masire D, Russell AH, Dryden-Peterson S, Efstathiou JA, Kayembe MK, Wilbur DC. Case records of the Massachusetts General Hospital. Case 16-2014. A 46-year-old woman in Botswana with postcoital bleeding. N Engl J Med. 2014 May 22; 370(21):2032-41. PMID: 24849087.
    Citations: 2     Fields:    Translation:Humans
  136. Seible DM, Gu X, Hyatt AS, Beard CJ, Choueiri TK, Efstathiou JA, Miyamoto DT, Mitin T, Martin NE, Sweeney CJ, Trinh QD, Beckman JA, Basaria S, Nguyen PL. Weight gain on androgen deprivation therapy: which patients are at highest risk? Urology. 2014 Jun; 83(6):1316-21. PMID: 24726149.
    Citations: 5     Fields:    Translation:Humans
  137. Gray PJ, Lin CC, Jemal A, Shipley WU, Fedewa SA, Kibel AS, Rosenberg JE, Kamat AM, Virgo KS, Blute ML, Zietman AL, Efstathiou JA. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys. 2014 Apr 01; 88(5):1048-56. PMID: 24661658.
    Citations: 17     Fields:    Translation:Humans
  138. Wang M, Kern AM, Hülskötter M, Greninger P, Singh A, Pan Y, Chowdhury D, Krause M, Baumann M, Benes CH, Efstathiou JA, Settleman J, Willers H. EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation. Cancer Res. 2014 May 15; 74(10):2825-34. PMID: 24648348.
    Citations: 19     Fields:    Translation:HumansAnimalsCells
  139. Ploussard G, Daneshmand S, Efstathiou JA, Herr HW, James ND, Rödel CM, Shariat SF, Shipley WU, Sternberg CN, Thalmann GN, Kassouf W. Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review. Eur Urol. 2014 Jul; 66(1):120-37. PMID: 24613684.
    Citations: 41     Fields:    Translation:Humans
  140. McDougal WS, Lee RJ, Efstathiou JA, Harisinghani M, Wu CL. Case records of the Massachusetts General Hospital. Case 2-2014. A 44-year-old man with a lesion on the penis. N Engl J Med. 2014 Jan 16; 370(3):263-71. PMID: 24428472.
    Citations: 1     Fields:    Translation:HumansCells
  141. Paly JJ, Hallemeier CL, Biggs PJ, Niemierko A, Roeder F, Martínez-Monge R, Whitson J, Calvo FA, Fastner G, Sedlmayer F, Wong WW, Ellis RJ, Haddock MG, Choo R, Shipley WU, Zietman AL, Efstathiou JA. Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2014 Mar 01; 88(3):618-23. PMID: 24411190.
    Citations: 7     Fields:    Translation:Humans
  142. Aizer AA, Paly JJ, Michaelson MD, Rao SK, Nguyen PL, Kaplan ID, Niemierko A, Olumi AF, Efstathiou JA. Medical oncology consultation and minimization of overtreatment in men with low-risk prostate cancer. J Oncol Pract. 2014 Mar; 10(2):107-12. PMID: 24399853.
    Citations: 4     Fields:    Translation:Humans
  143. Yu JB, Efstathiou JA, Bekelman JE. Proton radiotherapy for prostate cancer: how did we get here, and where do we go from here? Oncology (Williston Park). 2013 Dec; 27(12):1293-4. PMID: 24624550.
    Citations:    Fields:    Translation:Humans
  144. Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw. 2013 Nov; 11(11):1364-72. PMID: 24225970.
    Citations: 4     Fields:    Translation:Humans
  145. Gray PJ, Shipley WU, Efstathiou JA. T1 high-grade bladder cancer recurring after BCG therapy: a curative alternative to radical cystectomy exists. Con. Oncology (Williston Park). 2013 Sep; 27(9):873, 921. PMID: 24282983.
    Citations: 1     Fields:    Translation:Humans
  146. Gray PJ, Shipley WU, Efstathiou JA, Zietman AL. Recent advances and the emerging role for chemoradiation in nonmuscle invasive bladder cancer. Curr Opin Urol. 2013 Sep; 23(5):429-34. PMID: 23851382.
    Citations: 2     Fields:    Translation:Humans
  147. Chen RC, Shipley WU, Efstathiou JA, Zietman AL. Trimodality bladder preservation therapy for muscle-invasive bladder cancer. J Natl Compr Canc Netw. 2013 Aug; 11(8):952-60. PMID: 23946174.
    Citations: 13     Fields:    Translation:Humans
  148. Mitin T, Blute M, Lee R, Efstathiou J. Management of lymph node-positive prostate cancer: the role of surgery and radiation therapy. Oncology (Williston Park). 2013 Jul; 27(7):647-55. PMID: 23977759.
    Citations: 2     Fields:    Translation:Humans
  149. Wang Y, Efstathiou JA, Lu HM, Sharp GC, Trofimov A. Hypofractionated proton therapy for prostate cancer: dose delivery uncertainty due to interfractional motion. Med Phys. 2013 Jul; 40(7):071714. PMID: 23822418.
    Citations: 3     Fields:    Translation:Humans
  150. Aizer AA, Paly JJ, Efstathiou JA. Multidisciplinary care and management selection in prostate cancer. Semin Radiat Oncol. 2013 Jul; 23(3):157-64. PMID: 23763881.
    Citations: 7     Fields:    Translation:Humans
  151. Gray PJ, Efstathiou JA. Proton beam radiation therapy for prostate cancer-is the hype (and the cost) justified? Curr Urol Rep. 2013 Jun; 14(3):199-208. PMID: 23546839.
    Citations: 5     Fields:    Translation:Humans
  152. Lautenschlaeger T, George A, Klimowicz AC, Efstathiou JA, Wu CL, Sandler H, Shipley WU, Tester WJ, Hagan MP, Magliocco AM, Chakravarti A. Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival. Oncologist. 2013 Jun; 18(6):685-6. PMID: 23728940.
    Citations: 8     Fields:    Translation:Humans
  153. Efstathiou JA, Nassif DS, McNutt TR, Bogardus CB, Bosch W, Carlin J, Chen RC, Chou H, Eggert D, Fraass BA, Goldwein J, Hoffman KE, Hotz K, Hunt M, Kessler M, Lawton CA, Mayo C, Michalski JM, Mutic S, Potters L, Rose CM, Sandler HM, Sharp G, Tomé W, Tran PT, Wall T, Zietman AL, Gabriel PE, Bekelman JE. Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. J Oncol Pract. 2013 May; 9(3):e90-5. PMID: 23942508.
    Citations: 15     Fields:    Translation:Humans
  154. Hayman JA, Bosserman LD, Efstathiou JA. Summary of oral abstract session B: innovating to improve care quality. J Oncol Pract. 2013 May; 9(3):158-9. PMID: 23942498.
    Citations:    Fields:    Translation:Humans
  155. Zeng C, Giantsoudi D, Grassberger C, Goldberg S, Niemierko A, Paganetti H, Efstathiou JA, Trofimov A. Maximizing the biological effect of proton dose delivered with scanned beams via inhomogeneous daily dose distributions. Med Phys. 2013 May; 40(5):051708. PMID: 23635256.
    Citations: 2     Fields:    Translation:Humans
  156. Mitin T, Shipley WU, Efstathiou JA, Heney NM, Kaufman DS, Lee RJ, Zietman AL. Trimodality therapy for bladder conservation in treatment of invasive bladder cancer. Curr Urol Rep. 2013 Apr; 14(2):109-15. PMID: 23341373.
    Citations: 2     Fields:    Translation:Humans
  157. Mouw KW, Trofimov A, Zietman AL, Efstathiou JA. Clinical controversies: proton therapy for prostate cancer. Semin Radiat Oncol. 2013 Apr; 23(2):109-14. PMID: 23473687.
    Citations: 2     Fields:    Translation:Humans
  158. Wala J, Craft D, Paly J, Zietman A, Efstathiou J. Maximizing dosimetric benefits of IMRT in the treatment of localized prostate cancer through multicriteria optimization planning. Med Dosim. 2013; 38(3):298-303. PMID: 23540492.
    Citations: 6     Fields:    Translation:Humans
  159. Paly JJ, Efstathiou JA, Hedgire SS, Chung PW, O'Malley M, Shah A, Bekelman JE, Harisinghani M, Zietman AL, Beard C. Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields. Pract Radiat Oncol. 2013 Apr-Jun; 3(2 Suppl 1):S30. PMID: 24674542.
    Citations:    Fields:    
  160. Efstathiou JA, Gray PJ, Zietman AL. Proton beam therapy and localised prostate cancer: current status and controversies. Br J Cancer. 2013 Apr 02; 108(6):1225-30. PMID: 23481182.
    Citations: 9     Fields:    Translation:Humans
  161. Coen JJ, Paly JJ, Niemierko A, Kaufman DS, Heney NM, Spiegel DY, Efstathiou JA, Zietman AL, Shipley WU. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2013 Jun 01; 86(2):311-6. PMID: 23474117.
    Citations: 5     Fields:    Translation:Humans
  162. Gray PJ, Efstathiou JA, Shipley WU. The opportunity cost of androgen suppression in locally advanced prostate cancer. Asian J Androl. 2013 May; 15(3):356-7. PMID: 23435474.
    Citations:    Fields:    Translation:Humans
  163. Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shipley WU, Hahn SM, Zietman AL, Bekelman JE, Efstathiou JA. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer. 2013 May 01; 119(9):1729-35. PMID: 23436283.
    Citations: 28     Fields:    Translation:Humans
  164. Paly JJ, Zietman AL, Nguyen PL, Beard C, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and management of very low-risk prostate cancer. J Clin Oncol. 2013 Feb 20; 31(6_suppl):55. PMID: 28137047.
    Citations:    
  165. Hallemeier CL, Biggs PJ, Niemierko A, Roeder F, Martinez-Monge R, Whitson JM, Calvo FA, Fastner G, Wong W, Ellis RJ, Efstathiou JA. Outcomes for a multi-institutional cohort of patients treated with intra-operative radiation therapy for advanced or recurrent renal cell carcinoma. J Clin Oncol. 2013 Feb 20; 31(6_suppl):442. PMID: 28136946.
    Citations:    
  166. Fedewa SA, Shipley WU, Lin CC, Virgo KS, Kibel AS, Kamat AM, Rosenberg JE, Jemal A, Zietman AL, Efstathiou JA. Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: Associations with clinical variables and survival. J Clin Oncol. 2013 Feb 20; 31(6_suppl):248. PMID: 28136792.
    Citations:    
  167. Gray PJ, Efstathiou JA. Prostate cancer: Proton therapy--revolutionary advance or diminishing returns? Nat Rev Urol. 2013 Mar; 10(3):128-9. PMID: 23399730.
    Citations:    Fields:    Translation:Humans
  168. Paly JJ, Efstathiou JA, Hedgire SS, Chung PW, O'Malley M, Shah A, Bekelman JE, Harisinghani M, Shipley WU, Zietman AL, Beard C. Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields. Radiother Oncol. 2013 Jan; 106(1):64-8. PMID: 23321493.
    Citations: 1     Fields:    Translation:Humans
  169. Chabner BA, Efstathiou J, Dryden-Peterson S. Cancer in Botswana: the second wave of AIDS in Sub-Saharan Africa. Oncologist. 2013; 18(7):777-8. PMID: 23882018.
    Citations: 7     Fields:    Translation:HumansCells
  170. Efstathiou JA, Shipley WU. Words of wisdom. Re: Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. Eur Urol. 2013 Jan; 63(1):181-2. PMID: 23218494.
    Citations: 3     Fields:    
  171. Shah A, Paly JJ, Efstathiou JA, Bekelman JE. Physician evaluation of internet health information on proton therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Mar 15; 85(4):e173-7. PMID: 23245278.
    Citations: 3     Fields:    Translation:Humans
  172. Mitin T, Efstathiou JA, Shipley WU. Urological cancer. The benefits of intermittent androgen-deprivation therapy. Nat Rev Clin Oncol. 2012 Dec; 9(12):672-3. PMID: 23165125.
    Citations: 2     Fields:    Translation:Humans
  173. Gray PJ, Fedewa SA, Shipley WU, Efstathiou JA, Lin CC, Zietman AL, Virgo KS. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol. 2013 May; 63(5):823-9. PMID: 23200811.
    Citations: 44     Fields:    Translation:Humans
  174. Efstathiou JA. Postoperative radiation for prostate cancer. Lancet. 2012 Dec 08; 380(9858):1974-6. PMID: 23084480.
    Citations: 1     Fields:    Translation:Humans
  175. Gakis G, Efstathiou J, Lerner SP, Cookson MS, Keegan KA, Guru KA, Shipley WU, Heidenreich A, Schoenberg MP, Sagaloswky AI, Soloway MS, Stenzl A. ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2013 Jan; 63(1):45-57. PMID: 22917985.
    Citations: 97     Fields:    Translation:Humans
  176. Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol. 2012 Sep 01; 30(25):3071-6. PMID: 22851571.
    Citations: 35     Fields:    Translation:Humans
  177. Wilder RB, Buyyounouski MK, Efstathiou JA, Beard CJ. Radiotherapy treatment planning for testicular seminoma. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):e445-52. PMID: 22436787.
    Citations: 4     Fields:    Translation:Humans
  178. Bekelman JE, Deye JA, Vikram B, Bentzen SM, Bruner D, Curran WJ, Dignam J, Efstathiou JA, FitzGerald TJ, Hurkmans C, Ibbott GS, Lee JJ, Merchant TE, Michalski J, Palta JR, Simon R, Ten Haken RK, Timmerman R, Tunis S, Coleman CN, Purdy J. Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys. 2012 Jul 01; 83(3):782-90. PMID: 22425219.
    Citations: 22     Fields:    Translation:Humans
  179. Efstathiou JA, Paly JJ, Lu HM, Athar BS, Moteabbed M, Niemierko A, Adams JA, Bekelman JE, Shipley WU, Zietman AL, Paganetti H. Adjuvant radiation therapy for early stage seminoma: proton versus photon planning comparison and modeling of second cancer risk. Radiother Oncol. 2012 Apr; 103(1):12-7. PMID: 22391053.
    Citations: 5     Fields:    Translation:Humans
  180. Shah A, Efst